spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  darunavir 

 HSMN NewsFeed - 19 May 2017
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 29 Jun 2015
Aerie Pharmaceuticals Elects Julie McHugh and Michael M. du Toit to the Company’s Board of Directors
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 8 Jan 2014
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 16 Jan 2013
European Commission Approves PREZISTA(R) (darunavir) 800 mg Tablet Once a Day Reducing the Number of Pills Taken by People Living With HIV
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 11 Feb 2009
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Feb 2009
Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine)
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2008
European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 18 Nov 2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 29 Aug 2008
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 7 Feb 2008
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Feb 2008
Merck's ISENTRESS(R) (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 21 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 21 Jan 2008
AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 21 Dec 2007
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 18 Sep 2007
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Jul 2007
TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Mar 2007
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Mar 2007
Results from Two Phase III Studies on ISENTRESS(TM) (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 16 Feb 2007
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 14 Aug 2006
New Treatment Guidelines Support Use of FUZEON(R) to Achieve Undetectable HIV in Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.